Research ArticleRadiobiology/Dosimetry
Prediction of Tumor Control in 90Y Radioembolization by Logit Models with PET/CT-Based Dose Metrics
Yuni K. Dewaraja, Theresa Devasia, Ravi K. Kaza, Justin K. Mikell, Dawn Owen, Peter L. Roberson and Matthew J. Schipper
Journal of Nuclear Medicine January 2020, 61 (1) 104-111; DOI: https://doi.org/10.2967/jnumed.119.226472
Yuni K. Dewaraja
1Department of Radiology, University of Michigan, Ann Arbor, Michigan
Theresa Devasia
2Department of Biostatistics, University of Michigan, Ann Arbor, Michigan; and
Ravi K. Kaza
1Department of Radiology, University of Michigan, Ann Arbor, Michigan
Justin K. Mikell
3Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
Dawn Owen
3Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
Peter L. Roberson
3Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
Matthew J. Schipper
3Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 61, Issue 1
January 1, 2020
Prediction of Tumor Control in 90Y Radioembolization by Logit Models with PET/CT-Based Dose Metrics
Yuni K. Dewaraja, Theresa Devasia, Ravi K. Kaza, Justin K. Mikell, Dawn Owen, Peter L. Roberson, Matthew J. Schipper
Journal of Nuclear Medicine Jan 2020, 61 (1) 104-111; DOI: 10.2967/jnumed.119.226472
Prediction of Tumor Control in 90Y Radioembolization by Logit Models with PET/CT-Based Dose Metrics
Yuni K. Dewaraja, Theresa Devasia, Ravi K. Kaza, Justin K. Mikell, Dawn Owen, Peter L. Roberson, Matthew J. Schipper
Journal of Nuclear Medicine Jan 2020, 61 (1) 104-111; DOI: 10.2967/jnumed.119.226472
Jump to section
Related Articles
Cited By...
- PET/CT-Based Absorbed Dose Maps in 90Y Selective Internal Radiation Therapy Correlate with Spatial Changes in Liver Function Derived from Dynamic MRI
- A Multicenter Study on Observed Discrepancies Between Vendor-Stated and PET-Measured 90Y Activities for Both Glass and Resin Microsphere Devices
- Dosimetry in Radiopharmaceutical Therapy
- Pretreatment Levels of Soluble Tumor Necrosis Factor Receptor 1 and Hepatocyte Growth Factor Predict Toxicity and Overall Survival After 90Y Radioembolization: Potential Novel Application of Biomarkers for Personalized Management of Hepatotoxicity
- Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns